As of the beginning of September, Hoechst and Roussel in the UK merged to form a new company, Hoechst Roussel. Roussel Uclaf has a majority stake in the business holding 60%, and Hoechst 40%.
It is anticipated that the new company's consolidated turnover in 1994 should be in excess of L110 million ($172.7 million). Pharmaceutical sales in the UK in 1994 should be around L63 million. The merger moves Hoechst from a ranking in the UK of 51 and Roussel Uclaf of 35 to a consolidated position of 17.
The total number of staff in the UK is 1,100 and there are three main sites: in Denham, where the head office is based; in Swindon where production, research, and pharmaceutical development is located; and in Milton Keynes, which is the joint venture's distribution, drug development and clinical pharmacology center. There is also a distribution site in London which it is anticipated will move to Milton Keynes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze